antisense oligonucleotide targeting PD-1 pre-mRNA

This antisense oligonucleotide (ASO) is designed to target the pre-mRNA of Programmed Cell Death Protein 1 (PD-1), specifically focusing on the region involved in Exon 2 splicing. Developed by CLOVERNA Inc. using their DIRAC-dCas13-based screening platform, the ASO aims to disrupt the interaction of splice cis-trans elements. This disruption prevents the inclusion of Exon 2, which encodes the PD-L1-binding domain, thereby suppressing the expression of the functional PD-1 extracellular domain on the surface of CD8+ T cells. By inhibiting the PD-1/PD-L1 checkpoint at the RNA level, the therapy is intended to maintain the cytokine secretion capacity of lymphocytes and enhance antitumor immunity within the tumor microenvironment.

Other names

PD-1 ASOPD1 ASOPD 1 ASO